FilingReader Intelligence
Kangtai Bio gets approval for influenza vaccine trials
August 18, 2025 at 08:21 AM UTC•By FilingReader AI
Shenzhen Kangtai Biological Products and Lanzhou Bailin Biotech have secured approval from the National Medical Products Administration for clinical trials of their trivalent split influenza vaccine.
The vaccine targets individuals aged three years and older and will undergo Phase I and Phase III clinical trials.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
News Alerts
Get instant email alerts when Shenzhen Kangtai Biological Products publishes news
Free account required • Unsubscribe anytime